Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A phase II trial with the combination of plinabulin (plin) pegfilgrastim (peg): Evaluation of the reversal of peg's immune-suppressive potential by the addition of plin to peg. Blayney, D. W., Ogenstad, S., Shi, Y., Feng, J., Zhang, Q., Sun, T., Du, L., Huang, L., Mohanlal, R. AMER SOC CLINICAL ONCOLOGY. 2019
View details for DOI 10.1200/JCO.2019.37.8_suppl.4
View details for Web of Science ID 000489109600022